AbbVie Gains New Immunology Antibody Platform With DJS Buy
Deal Snapshot: AbbVie will acquire the privately-held UK antibody developer with preclinical assets.
You may also be interested in...
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
Bayer pharmaceuticals executive Marianne De Backer will succeed Scangos at Vir, tasked with advancing several mid-stage programs in areas like hepatitis B and influenza to late-stage development.